Another negative calcium channel blocker trial
Executive Summary
King's ACE inhibitor Altace (ramipril) and AstraZeneca's beta blocker Toprol (metoprolol) each significantly reduced the risk of kidney failure compared to Pfizer's calcium channel blocker Norvasc (amlodipine) in hypertensive patients with kidney disease and at least 1 g/day of protein in their urine, the NIH African American Study of Kidney Disease and Hypertension finds. NIH is terminating the Norvasc arm of the study in response to the findings. Pfizer points out that the finding is based on a relatively small number of patients with severe kidney disease
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth